Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | How can novel immunotherapy combinations improve outcomes in melanoma?

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on the potential of a fianlimab and cemiplimab in melanoma treatment, highlighting its potential to become a backbone for future clinical trials, including those exploring triplet therapies, brain metastases, and adjuvant or neoadjuvant settings. This combination may offer a pathway to approval based on ongoing randomized clinical trials. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Well, what I think this combination does, it has a roadway, a pathway to having approval based on randomized clinical trials that are still accruing and we have to read out. And that would bring another player into the sphere of melanoma therapeutics. And that’s important to look at the ability to utilize this as a backbone for further clinical trials, whether they’re triplet, whether they’re in brain metastases, whether they’re in adjuvant or neoadjuvant...

Well, what I think this combination does, it has a roadway, a pathway to having approval based on randomized clinical trials that are still accruing and we have to read out. And that would bring another player into the sphere of melanoma therapeutics. And that’s important to look at the ability to utilize this as a backbone for further clinical trials, whether they’re triplet, whether they’re in brain metastases, whether they’re in adjuvant or neoadjuvant.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.